Evidence map›Paper›PMID 40837745›Full record

ArticleWorld journal of gastrointestinal oncology2025

Intensive care unit outcomes and prognostic factors of esophageal cancer: A cross-sectional study in Chinese cancer-specialized hospitals.

Jiang-Feng Tang, Rui Xia, Xue-Zhong Xing, Chang-Song Wang, Gang Ma, Hong-Zhi Wang, Biao Zhu, Jiang-Hong Zhao, Dong-Min Zhou, Li Zhang and 25 more

Abstract read
In one paragraph

Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Jiang-Feng TangDepartment of Intensive Care Unit, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou 310000, Zhejiang Province, China.
Rui XiaDepartment of Intensive Care Unit, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300000, China.
Xue-Zhong XingDepartment of Intensive Care Unit, Cancer Hospital Chinese Academy of Medical Sciences, Beijing 100021, China.
Chang-Song WangDepartment of Intensive Care Unit, Harbin Medical University Cancer Hospital, Harbin 150081, Heilongjiang Province, China.
Gang MaDepartment of Intensive Care Unit, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
Hong-Zhi WangDepartment of Intensive Care Unit, Beijing Cancer Hospital, Beijing 100000, China.
Biao ZhuDepartment of Intensive Care Unit, Fudan University Affiliated Shanghai Cancer Hospital, Shanghai 200000, China.
Jiang-Hong ZhaoDepartment of Intensive Care Unit, Hunan Cancer Hospital, Changsha 410000, Hunan Province, China.
Dong-Min ZhouDepartment of Intensive Care Unit, Henan Cancer Hospital, Zhengzhou 450000, Henan Province, China.
Li ZhangDepartment of Intensive Care Unit, Hubei Cancer Hospital, Wuhan 430000, Hubei Province, China.
Ming-Guang HuangDepartment of Intensive Care Unit, Shanxi Province Cancer Hospital, Taiyuan 030000, Shanxi Province, China.
Rong-Xi QuanDepartment of Intensive Care Unit, Cancer Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830000, Xinjiang Uygur Autonomous Region, China.
Yong YeDepartment of Intensive Care Unit, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou 350014, Fujian Province, China.
Guo-Xing ZhangDepartment of Intensive Care Unit, Gaoxin District of Jilin Cancer Hospital, Changchun 130000, Jilin Province, China.
Zheng-Ying JiangDepartment of Intensive Care Unit, Chongqing University Cancer Hospital, Chongqing 400000, China.
Bing HuangDepartment of Intensive Care Unit, Guangxi Medical University Affiliated Tumor Hospital, Nanning 530000, Guangxi Zhuang Autonomous Region, China.
Shan-Ling XuDepartment of Intensive Care Unit, Sichuan Cancer Hospital and Institute, Chengdu 610041, Sichuan Province, China.
Yun XiaoDepartment of Intensive Care Unit, Yunnan Cancer Hospital, Kunming 650000, Yunnan Province, China.
Lin-Lin ZhangDepartment of Intensive Care Unit, Anhui Province Cancer Hospital, Hefei 230001, Anhui Province, China.
Rui-Yun LinDepartment of Intensive Care Unit, Cancer Hospital of Shantou University Medical College, Shantou 515000, Guangdong Province, China.
Shu-Liang MaDepartment of Intensive Care Unit, Jiangsu Cancer Hospital, Nanjing 210000, Jiangsu Province, China.
Yu-An QiuDepartment of Intensive Care Unit, Jiangxi Provincial Tumor Hospital, Nanchang 330000, Jiangxi Province, China.
Zhen ZhengDepartment of Intensive Care Unit, Liaoning Cancer Hospital and Institute, Shenyang 110000, Liaoning Province, China.
Ni SunDepartment of Intensive Care Unit, Huguang District of Jilin Cancer Hospital, Changchun 130000, Jilin Province, China.
Le-Wu XianDepartment of Intensive Care Unit, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou 510000, Guangdong Province, China.
Ji LiDepartment of Intensive Care Unit, Hainan Cancer Hospital, Haikou 570000, Hainan Province, China.
Ming ZhangDepartment of Intensive Care Unit, Hangzhou Cancer Hospital, Hangzhou 310000, Zhejiang Province, China.
Zhi-Jun GuoDepartment of Intensive Care Unit, Shandong First Medical University Affiliated Tumor Hospital, Jinan 300000, Shandong Province, China.
Yong TaoDepartment of Intensive Care Unit, Nantong Tumor Hospital, Nantong 256000, Jiangsu Province, China.
Xiang-Zhe ZhouDepartment of Intensive Care Unit, Gansu Provincial Cancer Hospital, Lanzhou 730000, Gansu Province, China.
Wei ChenDepartment of Intensive Care Unit, Beijing Shijitan Hospital (Capital Medical University Cancer Hospital), Beijing 100000, China.
Dao-Xie WangDepartment of Intensive Care Unit, Cancer Hospital of Zhengzhou, Zhengzhou 450000, Henan Province, China.
Ji-Yan ChiDepartment of Intensive Care Unit, Tumor Hospital of Mudanjiang City, Mudanjiang 157000, Heilongjiang Province, China.
Dong-Hao WangDepartment of Intensive Care Unit, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300000, China.
Kai-Zhong LiuDepartment of Intensive Care Unit, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou 310000, Zhejiang Province, China. liukaizhongicu@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEsophageal cancer patients had the highest intensive care unit (ICU) admitted rate in cancer patients. But their prognosis and evaluation methods were rarely studied.

aimTo depict the short-term mortality outcome and identify the potential prognostic factors of esophageal cancer patients admitted into ICU.

methodsA multicenter cross-sectional study was performed from May 10, 2021 to July 10, 2021 at ICU departments of 37 cancer specialized hospitals in China. Patients aged ≥ 14 years with ICU duration ≥ 24 hours were included. Clinical records of patients with primary esophageal cancer diagnosis were reviewed. Patients were separated into groups according to the 90 days survival. Characteristics between groups were compared. Single and multi-variate regression tests were applied to analyze the correlated factors of ICU outcomes. Predictive values of disease severity scores were assessed using receiver operating characteristic curve analysis.

resultsTotal 180 esophageal cancer patients were included. The 90 days mortality was 22.2%. Patients with mortality outcome showed differences from those survived mostly in disease severity and unplanned transfer from clinical ward. The current evaluation tools, including Sequential Organ Failure Assessment and Acute Physiology and Chronic Health Evaluation II scores had low accuracy in prediction of short-term death. ICU admitted esophageal cancer patients have poor prognosis, especially those with acute illness.

conclusionThe prognostic tools for these patients need to be further optimized.

Indexed as

Chinese cancer-specialized hospitalsDisease severity scoresEsophageal cancerIntensive care unitPrognostic factorsShort-term mortality

Identifiers

PMID40837745
PMCPMC12362544

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.